Literature DB >> 19307465

Hyperkalemia risk in chronic kidney disease: deterrent to the use of aldosterone receptor antagonism or not.

Domenic A Sica.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19307465     DOI: 10.1161/HYPERTENSIONAHA.108.128017

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


× No keyword cloud information.
  6 in total

1.  Evidence for a gastrointestinal-renal kaliuretic signaling axis in humans.

Authors:  Richard A Preston; David Afshartous; Rolando Rodco; Alberto B Alonso; Dyal Garg
Journal:  Kidney Int       Date:  2015-08-26       Impact factor: 10.612

Review 2.  Aging and antihypertensive medication-related complications in the chronic kidney disease patient.

Authors:  Zachary A Marcum; Linda F Fried
Journal:  Curr Opin Nephrol Hypertens       Date:  2011-09       Impact factor: 2.894

3.  What is the role of aldosterone excess in resistant hypertension and how should it be investigated and treated?

Authors:  Domenic A Sica
Journal:  Curr Cardiol Rep       Date:  2011-12       Impact factor: 2.931

4.  Hyperkalemia and Acute Kidney Injury with Spironolactone Use Among Patients with Heart Failure.

Authors:  Alex M Secora; Jung-Im Shin; Yao Qiao; G Caleb Alexander; Alex R Chang; Leslie A Inker; Josef Coresh; Morgan E Grams
Journal:  Mayo Clin Proc       Date:  2020-11       Impact factor: 7.616

5.  Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial.

Authors:  Bertram Pitt; Stefan D Anker; David A Bushinsky; Dalane W Kitzman; Faiez Zannad; I-Zu Huang
Journal:  Eur Heart J       Date:  2011-01-05       Impact factor: 29.983

Review 6.  Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis.

Authors:  Gemma Currie; Alison H M Taylor; Toshiro Fujita; Hiroshi Ohtsu; Morten Lindhardt; Peter Rossing; Lene Boesby; Nicola C Edwards; Charles J Ferro; Jonathan N Townend; Anton H van den Meiracker; Mohammad G Saklayen; Sonia Oveisi; Alan G Jardine; Christian Delles; David J Preiss; Patrick B Mark
Journal:  BMC Nephrol       Date:  2016-09-08       Impact factor: 2.388

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.